Division of Hematology/Oncology

Faculty

faculty photo

Donald Edward Tsai, M.D., Ph.D.

Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-0037
Fax: 215-615-5887
Education:
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
Post-Graduate Training
Intern in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1994-1995.
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1995-1996.
Post doctoral Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1996-2000.
Certifications
Internal Medicine, American Board of Internal Medicine, 1997.
Medical Oncology, American Board of Internal Medicine, 2001.
Medical Oncology Recertification, American Board of Internal Medicine, 2011.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Posttransplant Lymphoproliferative Disorder

Description of Clinical Expertise

Hematologic Malignancy and Stem Cell Transplantation

Selected Publications

Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M. : A pilot trial of quantitative EBV PCR in patients undergoing treatment for their malignancy: potential use of EBV PCR in multiple cancer types. Leukemia & Lymphoma 2014 Notes: in press.

Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS : Subcutaneous veltuzumab, a humanized anti-CD20 antibody, for treatment of refractory pemphigus vulgaris. JAMA Dermatology 2014 Notes: in press.

Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL. : Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014 Notes: in press.

Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE: Plasmacytic Posttransplant lymphoproliferative disorder: a case series of nine patients. Transplant International 26: 616-622, 2013.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American Journal of Hematology 88: 657-660, 2013.

Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, Kotloff RM, Hadjiliadis D, Stadtmauer EA. Schuster SJ, Tsai DE. : Post-Transplant Lymphoproliferative Disorder Following Lung Transplantation: A Review of 35 Cases. Journal of Heart and Lung Transplantation 31: 296-304 2012.

Tizon R, Frey N, Heitjan DF, Tan KS, Goldsteind SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D. Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplantation 2012 Notes: in press.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS. : Adjuvant rituximab therapy of pemphigus: a single center experience with 31 patients. Archives of Dermatology 2012 Notes: in press.

Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, Heitjan DF, Tsai DE. : Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. American Journal of Transplantation 11: 817-825, 2011.

Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE. : Reduction of immunosuppression as initial therapy for Posttransplant lymphoproliferative disorder. American Journal of Transplantation 11: 336-347, 2011.

back to top
Last updated: 09/08/2014
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter